Smart dosing for seniors: antibiotic study aims to get it just right
NCT ID NCT07494981
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a personalized approach to dosing the antibiotic ceftazidime-avibactam in patients aged 60 and older. Researchers will measure drug levels in the blood and use computer models to adjust each person's dose, aiming to improve effectiveness and reduce side effects. The goal is to create a smarter, safer dosing system for older adults.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CEFTAZIDIME-AVIBACTAM are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••